Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination

Inclusion Criteria: * The patient received a fluorouracil or capecitabine overdose (regardless of the presence of symptoms) or * The patient is exhibiting early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration * Judged by the Investigator to have the initiative and means to be compliant with the protocol * Able to take oral medications * Able to start treatment with uridine triacetate within 96 hours after the end of fluorouracil or capecitabine administration * Provides written informed consent (patient or legally authorized representative) Exclusion Criteria: * Has a known allergy to uridine triacetate or any of its excipients * Unable to have the initiative and means to be compliant with the protocol * Unable to be compliant with taking oral medications * More than 96 hours have elapsed since the completion of 5-FU dosing * Unable to provide written informed consent (patient or legally authorized representative)